ImmuCell (NASDAQ:ICCC) Stock Passes Above 200-Day Moving Average – Here’s Why

ImmuCell Corporation (NASDAQ:ICCC)’s stock price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.11 and traded as high as $6.20. ImmuCell shares last traded at $6.02, with a volume of 8,934 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

ImmuCell Trading Down 0.3%

The stock has a market capitalization of $54.48 million, a P/E ratio of 23.15 and a beta of 0.18. The firm’s 50-day simple moving average is $5.95 and its 200 day simple moving average is $6.10. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $5.51 million during the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

Institutional Trading of ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC lifted its holdings in shares of ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,852 shares of the biotechnology company’s stock after purchasing an additional 2,907 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 as of its most recent SEC filing. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.